posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.915 0 Advanced Cell Technology Names Current Chief Executive Officer William M. Caldwell IV as Chairman of the Board
Nov 9, 2006 06:30:26 (ET)
ALAMEDA, Calif., Nov 09, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that current Chief Executive Officer, William M. Caldwell IV, has been appointed to serve as the Chairman of the Board in a unanimous vote by the company's directors.
Mr. Caldwell will assume the role of Chairman from Dr. Michael D. West, who will continue in his role as President, Chief Scientific Officer and a director of Advanced Cell Technology. Dr. West, a recognized leader in the fields of embryonic stem cell science and regenerative medicine, will continue his focus on and commitment to ACTC's research and development programs.
"I want to thank Dr. West for his leadership at Advanced Cell Technology during his service as Chairman of the Board. We are all grateful for his current and continuing contributions," said Mr. Caldwell. "My role as CEO with ACTC's business and scientific teams has been extremely rewarding, and I welcome the Board's support in their decision to expand my duties to the position of Chairman."
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
i got 4k at .85 today. hopefully ill have to average up (a lot), not average down:) this one could be the bigg one someday. im goin longggggggggg
IP: Logged |
posted
Besides the fact that this company is sound from a fundamental standpoint, it also looks terrific from a technical perspective...over the month it has formed a pretty nice looking triangle pattern, with higher lows and a horizontal top. These formations usually indicate an outbreak to the upside.
IP: Logged |
posted
Advanced Cell Technology Comments on the Results of the Midterm Elections
Nov 14, 2006 09:41:20 (ET)
ALAMEDA, Calif., Nov 14, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) Chairman and CEO William Caldwell today commented on the midterm United States Congressional elections held Tuesday, November 7, 2006. "Embryonic stem cells hold the potential to provide a well-characterized and reproducible source of replacement cells for clinical studies and the treatment of devastating diseases and injuries such as heart disease, cancer, macular degeneration, Parkinson's disease, Alzheimer's disease, and diabetes. We have been encouraged by our progress to date, though there is little doubt that in the United States progress in our field has been hampered by the ban on federal funding of research on new embryonic stem cell lines. I believe the changing political tide brings us yet another step closer to federal funding for embryonic stem cell research and ultimately to developing therapies for devastating and life threatening indications."
Advanced Cell Technology strongly supported both H.R. 810 and S. 2754, which were legislative efforts put before Congress in July 2006 to support the use of federal funds to research frozen hESC lines and to promote medical research and development of alternative hESC lines through techniques that do not harm a human embryo or fetus.
"While we were disappointed that H.R. 810 and S. 2754 were not enacted into law, we have been encouraged by the bipartisan support of recent legislative efforts to provide federal funding for embryonic stem cell research," Mr. Caldwell continued. "We are also encouraged by the widespread support of embryonic stem cell research by the American public as evidenced by the results of the recent Congressional elections. It may be only a matter of time before the federal government provides the expanded funding that scientists in laboratories in universities at pharmaceutical and biotechnology companies across the country require to move novel therapies from the lab to the clinic and, ultimately, to the bedside. Eventually, this funding could accelerate the programs for companies researching both embryonic and adult stem cell therapies including but not limited to Advanced Cell Technology, Geron Corporation, StemCells Inc., and Aastrom Biosciences. We will continue to work with our technological, ethical, and legislative partners to focus on driving therapies to the clinic."
Advanced Cell Technology's recent milestones include publication of the company's single cell blastomere technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The company also recently published positive progress in its retinal pigment epithelial (RPE) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina. Advanced Cell Technology also continues to investigate the use of human embryonic stem cell-derived hemangioblasts for vascular restoration of organs and limbs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Companies Notifying SEC Of Late Reports -5- -2-
Nov 16, 2006 14:02:00 (ET)
WASHINGTON (Dow Jones)--Companies and other entities that are unable to file their quarterly and annual reports on time must notify the Securities and Exchange Commission. A deadline for many larger-capitalization companies to file quarterly reports was Nov. 9; another deadline was Tuesday.
The following companies, listed alphabetically, submitted late-filing notifications or amended those notifications this week. A U.S. stock exchange ticker symbol or CIK number is provided.
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
all pharms/biotechs ALWAYS have huge losses. its the nature of that beast. ACTC will have to drop to a bottom begore I ever tie up my money in this snail.
-------------------- Do not invest on any of my suggestions
IP: Logged |
posted
New York Times Cites Advanced Cell's Review in Nature On an Approach to Generate Human Embryonic Stem Cells Without Destroying the Embryo
Nov 24, 2006 08:33:07 (ET)
ALAMEDA, Calif., Nov 24, 2006 (BUSINESS WIRE) -- The New York Times has commented on Advanced Cell Technology, Inc's (ACTC, Trade ) review in Nature surrounding its approach to generate human embryonic stem cells without destroying the embryo, stating, "the Journal affirmed the report's scientific validity."
The paper has been published in hard copy along with a supplement and addendum in the November 23, 2006 print issue of Nature, and demonstrates that single blastomeres can be used to establish human embryonic stem cell lines. The paper was originally published online in Nature, in August 2006.
The technique is modeled on PGD (pre-implantation genetic diagnosis), an approach for single-cell biopsy using micromanipulation that does not interfere with the developmental capacity of the parent embryo.
The following link may be used to access the full New York Times article, commenting on the Nature paper.
http://www.nytimes.com/2006/11/22/science/23stemcnd.html?hp&ex= 1164258000&en=13d6158df8d9e8b1&ei=5094&partner=homepage(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 Or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Good volume today so far especially for this Friday. Hopefully that New York Times article was the "all aboard" call. I've been settled in my seat and patiently waiting for this train to leave the station. Looking forward to see what happens on Monday after more people get back to their seats.
IP: Logged |
NEW YORK, Nov 29, 2006 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 10th Annual Biotech/Specialty Pharma Conference on December 12 to 13, 2006.
What does the future have in store for the biotech industry? Don't miss this chance to hear Michael D. West, PhD, president of Advanced Cell Technology and author of The Immortal Cell: One Scientist's Quest to Solve the Mystery of Human Aging, discuss the emerging field of stem cell research. Other presentations include companies focused on hormone therapy, drug delivery and treatments for HIV/AIDS and cancer.
The following companies are presenting on day one:
Aradigm Corporation (ARDM, Trade ); BioSante Pharmaceuticals, Inc. (BPA, Trade ); CytRx Corporation (CYTR, Trade ); DNAPrint Genomics, Inc. (DNAG, Trade ); DRAXIS Health Inc. (DRAX, Trade ); DURECT Corporation (DRRX, Trade ); Heska Corporation (HSKA, Trade ); The Immune Response Corporation (IMNR, Trade ); Viral Genetics, Inc. (VRAL, Trade ); and Xechem International, Inc. (XKEM, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology, Inc. (ACTC, Trade ); Cleveland BioLabs, Inc. (CBLI, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); EntreMed, Inc. (ENMD, Trade ); Neuro-Hitech Pharmaceuticals, Inc. (NHPI, Trade ); Provectus Pharmaceuticals, Inc. (PVCT, Trade ); The Quigley Corporation (QGLY, Trade ); and XTL Biopharmaceuticals Ltd. (XTLB, Trade ).
The conference will be held on December 12, 2006, 8:30 a.m. to 5:10 p.m., and December 13, 2006, 8:30 a.m. to 4:30 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 5, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials. A complete agenda is available at
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About NYSSA
NYSSA, established in 1937, is the premier independent forum for the exchange of information among investment decision-makers. A not-for-profit educational organization with over 9,500 members, NYSSA is committed to the promotion of best practices and the highest professional and ethical standards in the investment industry. NYSSA is the largest of the more than 134 societies worldwide that make up CFA Institute, which has more than 83,000 members.
SOURCE: The New York Society of Security Analysts
The New York Society of Security Analysts Dawn Cavalieri, 212-541-4530, ext. 20 press*nyssa.org
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Advanced Cell Technology's Robert Lanza, M.D., to Deliver Keynote Address at the University of Florida's Vision Research Symposium on December 7, 2006
Dec 7, 2006 08:33:15 (ET)
ALAMEDA, Calif., Dec 07, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Robert Lanza, M.D., VP of Research and Scientific Development, will deliver the keynote address at the University of Florida's Vision Research Symposium, titled "Advances in the Use of Stem Cells for Repair and Regeneration of the Eye," December 7, 2006, at 12:10 PM, at the Hilton University of Florida Conference Center, Gainesville, Florida. Dr. Lanza's presentation is titled "The Use of Embryonic Stem Cells in Regenerative Medicine." The recent progress that has been made in using embryonic stem-cell derived cells to rescue visual function in animals will be discussed, as well as the scientific promise --and challenges -- that remain before these and other human stem cell therapies can enter the clinic.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210 or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Advanced Cell Technology Executives to Present Keynote Address and Company Presentation at New York Society of Security Analysts (NYSSA) Conference
Dec 11, 2006 08:32:25 (ET)
ALAMEDA, Calif., Dec 11, 2006 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Michael West Ph.D., President and Chief Scientific Officer, will deliver the keynote luncheon speech at the New York Society of Security Analysts Conference (NYSSA), on December 12, 2006 at 12:30 PM. William M. Caldwell, IV, Chief Executive Officer, will deliver the company presentation on December 13, 2006 at 1:40 PM. The conference is being held at the NYSSA headquarters located at 1177 Sixth Avenue in New York.
Widely regarded as a leader in the field, prior to founding ACTC, Dr. West organized and managed the research between Geron Corporation (GERN, Trade ) and its academic collaborators, James Thomson and John Gearhart, that led to the first isolation of human embryonic stem and human embryonic germ cells. Dr. West will be speaking on the "Emerging Field of Stem Cells".
William Caldwell will be delivering the company presentation, highlighting Advanced Cell's leadership and advancement in the stem cell field. The company recently published a paper in Nature regarding the use of embryonic stem cells to rescue visual function in animals, and in August announced an approach to generate human embryonic stem cells that does not destroy the embryo.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications: Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Advanced Cell Technology Invited to Deliver Keynote Address at Prestigious International Stem Cell Therapy and Regenerative Medicine Conference in London
Dec 13, 2006 06:30:34 (ET)
ALAMEDA, Calif., Dec 13, 2006 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC), Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, announced today that William Caldwell IV, Chairman and Chief Executive Officer, has been invited to present an overview of the Company's proprietary stem cell science and therapeutic programs at the upcoming 4th Annual Commercialization of Tissue Engineering and Cell Therapy, to be held December 14 and 15, 2006, in London.
The conference is designed to bring together research, academic and business leaders who are driving progress in cell-based sciences and industry. Attendees and speakers will address fundamental challenges and opportunities of producing cell-based therapies, with a focus on the strategic path to bring products to market.
In his keynote address, Mr. Caldwell will discuss ACTC's unique technologies as well as its overall strategies for developing medically valuable therapies for a number of market segments in medicine and health care. ACTC has pioneered a range of innovations relating to human embryonic stem cells, and is committed to taking a leadership role in the development of stem cell based therapies to cure or treat a range of serious diseases, injuries and degenerative medical conditions.
Mr. Caldwell's presentation is scheduled for December 15, 2006, at 9:10 am GMT. The conference will be held at the Grange Holborn Hotel in London.
"I believe that we are at a pivotal point in our industry's evolution, where research has begun to show the vast potential of stem cell-based therapies to offer important advances in medical care," said Mr. Caldwell. "At ACTC, we are already employing innovative solutions in both basic science as well as product applications, and I look forward to sharing our ideas with my colleagues in the extended international community of scientists and business leaders."
ACTC's mission is to develop stem cell based treatments and therapies for a broad range of disease and injuries. Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. One of ACTC's lead development programs applies human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa. Another development program focuses on the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
